SUBSEQUENT EVENT

6 Months Ended

Jun. 30, 2015

Subsequent Events [Abstract]

SUBSEQUENT EVENT

13. SUBSEQUENT EVENT

In July 2015, we purchased from Teva the ANDAs for 22 previously marketed generic drug products for $25 million in cash and a percentage of future gross profits from product sales. The transaction was funded by cash on hand.